The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone

Autor: Leta, Valentina, van Wamelen, Daniel J, Aureli, Federico, Metta, Vinod, Trivedi, Dhaval, Cortelli, Pietro, Rodriguez-Blazquez, Carmen, Rizos, Alexandra, Ray Chaudhuri, K
Přispěvatelé: International Parkinson and Movement Disorder Society, National Institute for Health Research (Reino Unido), NIHR - UCL Biomedical Research Centre (Reino Unido), Parkinsons Foundation, King College London, NHS - Foundation Trust
Rok vydání: 2023
Předmět:
Zdroj: Journal of Neural Transmission, 130, 7, pp. 925-930
ISSN: 1435-1463
0300-9564
Popis: Objective To evaluate the long-term, real-life effects on non-motor symptoms (NMS) of opicapone compared to entacapone in levodopa-treated people with Parkinson’s disease (PwP). Methods A retrospective data analysis, with pre- and post-opicapone initiation data of 17 PwP with motor fluctuations compared to a comparable group of 18 PwP introduced on entacapone. The primary outcome was changes in the NMS Scale (NMSS) total score after 1-year follow-up. Secondary outcomes included changes in the NMSS domains, and Parkinson’s Disease Sleep Scale (PDSS) total and item scores after the same time span. Results Groups were comparable for baseline demographics and Parkinson’s-related features (p ≥ 0.314) as well as duration of follow-up (1.33 ± 0.66 years for PwP on opicapone and 1.23 ± 0.49 years for those on entacapone; p = 0.858). PwP who were introduced on opicapone showed no changes in NMSS and PDSS total scores after 1 year (p = 0.605 and p = 0.507, respectively), whereas PwP who were introduced on entacapone showed significant worsening of NMSS and PDSS total scores at follow-up (p = 0.005 and p = 0.001, respectively). In neither group changes in individual NMSS domains from baseline to follow-up were observed (p ≥ 0.288 for entacapone and p ≥ 0.816 for opicapone, respectively). In PwP on entacapone significant worsening was seen in the distressing dreams, hallucinations, and limb numbness items of the PDSS (p ≤ 0.05). Conclusions Introduction of opicapone in real-life PwP with motor fluctuations seems to stabilise NMS burden and aspects of sleep dysfunction, in contrast to entacapone where there was a worsening of NMS burden and PDSS scores over 1 year follow-up.
Databáze: OpenAIRE
Externí odkaz: